Hepatic ischemia-reperfusion injury
Conditions
Interventions
Trial Group:Propofol phosphate disodium: induction dose 10-15 mg/kg, maintenance infusion rate 10-20 mg/kg/h
Control Group:Propofol: induction dose 1-2.5 mg/kg, maintenance infusion rate 6-12 mg/kg/h
Sponsors
The First People's Hostipal of Zhaoqing
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age between 40 and 75 years old, ASA score II - III, BMI 19-28 kg/m^2, gender not limited. The patient meets the medical criteria for liver surgery and is a first-time liver surgeon. 3. The patient or their legal representative has signed the informed consent form. 4. The patient has not participated in other clinical trials. 5. No communication barriers, no history of mental or neurological disorders. 6. No history of long-term use of sedative drugs. 7. No history of drug allergy. 8. No history of radiotherapy, chemotherapy or interventional surgery
Exclusion criteria
Exclusion criteria: 1. Patients with combined heart, lung and blood system diseases or severe liver cirrhosis and renal insufficiency; 2. Patients suspected of or with a history of alcohol or drug abuse; 3. Pregnant or lactating women; 4. History of liver tumor rupture and bleeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function biochemical markers: ALT, AST, bilirubin;Hepatic pathological injury severity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Oxidative stress level;Inflammatory response level;Perioperative indicators: surgical duration, anesthesia duration, lactate levels before and after hepatic hilum clamping, tumor size, number and total duration of hepatic hilum clamping, total fluid balance during surgery, postoperative analgesia efficacy;Postoperative complication rate, hospital stay duration, postoperative liver function, and quality of life; | — |
Countries
China
Contacts
Public ContactDeng Haihong
The First People's Hostipal of Zhaoqing
Outcome results
None listed